1. Home
  2. SLN vs FF Comparison

SLN vs FF Comparison

Compare SLN & FF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLN
  • FF
  • Stock Information
  • Founded
  • SLN 1994
  • FF N/A
  • Country
  • SLN United Kingdom
  • FF United States
  • Employees
  • SLN N/A
  • FF N/A
  • Industry
  • SLN Biotechnology: Pharmaceutical Preparations
  • FF Major Chemicals
  • Sector
  • SLN Health Care
  • FF Industrials
  • Exchange
  • SLN Nasdaq
  • FF Nasdaq
  • Market Cap
  • SLN 165.3M
  • FF 180.0M
  • IPO Year
  • SLN N/A
  • FF N/A
  • Fundamental
  • Price
  • SLN $3.70
  • FF $4.12
  • Analyst Decision
  • SLN Buy
  • FF Strong Buy
  • Analyst Count
  • SLN 5
  • FF 1
  • Target Price
  • SLN $32.60
  • FF $0.80
  • AVG Volume (30 Days)
  • SLN 256.3K
  • FF 271.1K
  • Earning Date
  • SLN 05-08-2025
  • FF 05-12-2025
  • Dividend Yield
  • SLN N/A
  • FF 5.83%
  • EPS Growth
  • SLN N/A
  • FF N/A
  • EPS
  • SLN N/A
  • FF 0.35
  • Revenue
  • SLN $27,701,000.00
  • FF $243,339,000.00
  • Revenue This Year
  • SLN N/A
  • FF N/A
  • Revenue Next Year
  • SLN N/A
  • FF N/A
  • P/E Ratio
  • SLN N/A
  • FF $11.77
  • Revenue Growth
  • SLN N/A
  • FF N/A
  • 52 Week Low
  • SLN $1.97
  • FF $3.77
  • 52 Week High
  • SLN $24.38
  • FF $6.40
  • Technical
  • Relative Strength Index (RSI)
  • SLN 55.23
  • FF 52.30
  • Support Level
  • SLN $3.54
  • FF $3.91
  • Resistance Level
  • SLN $4.15
  • FF $4.19
  • Average True Range (ATR)
  • SLN 0.33
  • FF 0.12
  • MACD
  • SLN 0.06
  • FF 0.02
  • Stochastic Oscillator
  • SLN 53.62
  • FF 74.11

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About FF FutureFuel Corp. Common shares

FutureFuel Corp makes and sells diversified chemical products, bio-based fuel products, and specialty chemical products. The company is organized into two segments based on product type: biofuels and chemicals. The biofuel segment sells biodiesel and other petroleum products. Its fuels are made from a mix of diesel, vegetable oils, and grease feedstock. The chemicals segment sells products that are used in the production of agricultural chemicals, which include herbicides, coatings, and cleaning products, such as detergents.

Share on Social Networks: